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We describe a virucidal small molecule, PD 404,182, that is effective against hepatitis C virus (HCV) and human immunodefi-
ciency virus (HIV). The median 50% inhibitory concentrations (IC50s) for the antiviral effect of PD 404,182 against HCV and
HIV in cell culture are 11 and 1M, respectively. The antiviral activity of PD 404,182 is due to the physical disruption of virions
that is accompanied to various degrees (depending on the virus and exposure temperature/time) by the release of viral nucleic
acids into the surrounding medium. PD 404,182 does not directly lyse liposomal membranes even after extended exposure, and
it shows no attenuation in antiviral activity when preincubated with liposomes of various lipid compositions, suggesting that the
compound inactivates viruses through interaction with a nonlipid structural component of the virus. The virucidal activity of
PD 404,182 appears to be virus specific, as little to no viral inactivation was detected with the enveloped Dengue and Sindbis vi-
ruses. PD 404,182 effectively inactivates a broad range of primary isolates of HIV-1 as well as HIV-2 and simian immunodefi-
ciency virus (SIV), and it does not exhibit significant cytotoxicity with multiple human cell lines in vitro (50% cytotoxic concen-
tration,>300M). The compound is fully active in cervical fluids, although it exhibits decreased potency in the presence of
human serum, retains its full antiviral potency for 8 h when in contact with cells, and is effective against both cell-free and cell-
associated HIV. These qualities make PD 404,182 an attractive candidate anti-HIVmicrobicide for the prevention of HIV trans-
mission through sexual intercourse.
Human pathogenic viruses that acquire resistance to antiviralagents by rapid evolution in vivo pose a serious health prob-
lem with no simple cure. Antivirals targeting features of these
viruses that can be altered through changes in the viral genetic
code often exhibit limited efficacy. Hepatitis C virus (HCV) and
human immunodeficiency virus (HIV) are two such viruseswhich
cause disorders of the liver and immune system, respectively, and
collectively afflict 2 to 3% of the world’s population (40 and
http://www.unaids.org/globalreport/Global_report.htm). For HCV,
the current interferon/ribavirin combination therapy exhibits
limited efficacy, and the two recently approved small-molecule
drugs, both serine protease inhibitors—telaprevir and boce-
previr (12, 23)—foster the development of resistant viral
strains within days when administered alone (37, 43). For HIV,
there are currently more than 20 approved antiretroviral drugs,
forming the basis of highly active antiretroviral therapy
(HAART). Despite the availability of this large repertoire of
anti-HIV drugs, drug-resistant mutant strains of HIV still
emerge over time. Approximately 4 to 5 million HIV patients
are coinfected with HCV (10), and these individuals tend to
exhibit a higher rate of viral persistence, increased viral load,
and higher susceptibility to death compared to individuals in-
fected with only one of these viruses (31). Thus, there is an
urgent need to develop antivirals that treat and prevent infec-
tion by HCV and HIV through new modes of action.
Antiviral molecules targeting critical virus structural elements
tend to be effective against several viruses and do not usually foster
the emergence of drug-resistant viral isolates. One group of mol-
ecules inhibit virus-cell fusion by inducing positive membrane
curvature, thus increasing the activation energy barrier for fusion
with cell membranes (16, 27, 43). These molecules, which include
rigid amphipathic fusion inhibitors (RAFIs) (42) and lysophos-
phatidylcholine (16), tend to have large hydrophilic heads and
hydrophobic tails. LJ001, a recently discovered broad-spectrum
small-molecule antiviral, inhibits the fusogenic activity of envel-
oped viruses by intercalating into the lipid membrane while leav-
ing virion particles grossly intact (46). Alkylated porphyrins ex-
hibit strong antiviral activity against several enveloped viruses
through an unknown mechanism, perhaps by interfering with
specific structures on the virus surface (17). Amphipathic peptides
derived from HCV NS5A protein were shown to physically dis-
rupt virions and were active against a variety of enveloped viruses
(3, 7). Another approach to interfering with membrane elements
required for virus infection is to target exposed anionic phospho-
lipids widely expressed on infected host cells and viral envelopes,
as was done with bavituximab, a chimeric antibody which rescues
mice from Pichinde virus and mouse cytomegalovirus infection
(41).
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Previously, we identified a small-molecule inhibitor of HCV
entry, PD 404,182 (PD), from a screen of 1,280 small-molecule
compounds (LOPAC1280) known to be pharmacologically active
in a variety of cellular processes (8). Here, we report that PD, an
inhibitor of bacterial 2-keto-3-deoxyctulosonic acid (KDO) 8-P
synthase (1a), is a virucidal compound that compromises the
structural integrity of both HCV and HIV, likely by interacting
with a nonlipid structural element of these viruses. In vitro studies
revealed that PD physically disrupts variously pseudotyped lenti-
viruses and exposes the viral genomic RNA in a time- and
temperature-dependent manner. Viral lysis is much less pro-
nounced with cell culture-produced HCV (HCVcc), despite a
clear inactivation ofHCVcc infectivity on the preincubation of PD
with viral supernatants. PD strongly inactivates multiple isolates
of primary HIV-1 that utilize different coreceptors, HIV-2, and
simian immunodeficiency virus (SIV), with a 50% inhibitory con-
centration (IC50) of1Mand a selectivity index (50% cytotoxic
concentration [CC50]/IC50) of300. A high antiviral potency and
low cytotoxicity, combined with a unique mode of action, make
PD a welcome addition to our current arsenal of antivirals to
combat infection by HCV and HIV.
MATERIALS AND METHODS
Reagents. PD 404,182 and Triton X-100 were purchased from Sigma-
Aldrich (St. Louis, MO). C5A was synthesized at the Scripps Research
Institute. PD and C5A were dissolved in 100% dimethylsulfoxide
(DMSO) to final concentrations of 30 mM and 10 mg/ml, respectively,
and stored at 20°C. Unless otherwise specified, growth medium for all
cell culture work was Dulbecco’s modified essential medium (DMEM)
containing 4,500 mg/liter glucose, 4.0 mM L-glutamine, and 110 mg/liter
sodium pyruvate (Thermo Scientific HyClone), and it was supplemented
with 10% fetal bovine serum (FBS) (Atlanta Biologicals) and 1 nones-
sential amino acids (Thermo Scientific HyClone). Conditioned complete
growth medium (DMEM plus 10% FBS) was harvested on day 3 (with
cells at 100% confluence) postseeding from Huh-7.5 cells initially seeded
at20% confluence.
Production of HCVcc and pseudotyped lentiviruses. The produc-
tion and titer determination of Jc1 HCVcc (32) was performed as previ-
ously described (8). Unless otherwise specified, all lentiviral pseudopar-
ticles were generated from 293T cells by the cotransfection of plasmids
carryingHIV gag-pol, a provirus (pTRIP-Gluc, pV1-Gluc, or pV1-B), and
an appropriate envelope protein. For the production of envelope glyco-
proteins ofmurine leukemia virus (MLVpp), Sindbis virus (SINVpp), and
HIV (HIVpp), plasmids encoding the viral envelope proteins pHIT456
(5), pIntron-SINV-env (29), and HIV BaL.01 (25), respectively, were
used.
pV1 is aminimalHIV-1 provirus lackingmostHIV genes except for all
necessary cis acting sequences, such as Tat, Rev, and Vpu open reading
frames (ORFs) (9, 13, 47). In pV1-B and pV1-Gluc, the Nef gene was
replaced by an irrelevant peptide and the Gluc gene, respectively. The
titers of vesicular stomatitis virus envelope glycoprotein (VSV-Gpp) and
HIVpp harboring pV1-B or pV1-Gluc was measured on a TZM-bl indi-
cator cell line using the lacZ reporter in a limiting dilution assay (36).
HCVcc infection assay. As shown in Fig. 1A, Jc1 Gluc HCVcc (105
50% tissue culture infectious doses [TCID50]/ml) (28) was concentrated
4-fold using an ultracentrifugation column with a 100-kDa cutoff mem-
brane and washed twice with phenol red-free DMEM to remove any PD-
inactivating molecules present in the virus supernatant. Concentrated
virus was incubated with PD or DMSO at 37°C for 30 min, diluted 1,000-
fold with fresh complete growth medium, and used to infect naïve Huh-
7.5 cells in 24-well (105 cells/well) or 96-well (2.8 104 cells/well) plates 4
to 6 h after seeding. The control samples contain virus and PD of the same
final titers/concentrations, but with the virus and PD separately diluted
1,000-fold prior to mixing. Viral infectivity was quantified by measuring
the supernatant activity of the Gluc reporter or immunostaining infected
cells for NS5A with 9E10 (anti-NS5A) antibody (26) 72 h postinfection.
Spinoculation. PD-treated virus samples (HCVcc or VSV-Gpp) were
cooled on ice for 5 to 10 min and added to chilled target cells seeded in
FIG 1 PD is virucidal against HCVcc and pseudotyped lentivirus. (A and B)
Effect on HCVcc infectivity. Jc1 Gluc HCVcc was incubated with PD or 0.5%
DMSO at 37°C for 30min, diluted 1,000-fold, and used to infect Huh-7.5 cells.
The control samples contain virus and PD of the same final titers/concentra-
tions but with the virus and PD separately diluted 1,000-fold prior to mixing.
The infectivity was quantified by measuring the supernatant activity of the
Gluc reporter 72 h postinfection (A) and immunostaining for NS5A (B).
HCV-infected cells are dark brown after immunostaining. The inset in panel A
shows the chemical structure of PD. (C) Effect on extracellular VSV-Gpp and
HCVcc. VSV-Gpp (harboring pV1-B; 106 TCID50/ml; undiluted) or Jc1
HCVcc (104 TCID50/ml; 10-fold diluted)was incubatedwith PD (150Min
0.5% DMSO) or 0.5% DMSO in the presence of 7 ng/ml RNase A at 37°C for
30 min. The viral RNA levels of the virus-PD and virus-DMSOmixtures were
quantified by qRT-PCR, while the infectivity of the same mixtures was deter-
mined by the spinoculation of Huh-7.5 cells and the quantification of intra-
cellular viral RNA by qRT-PCR 48 h later. All data are the means standard
deviations (SD) from two independent experiments carried out in duplicate.
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96-well plates. Spinoculation was carried out at 300  g for 2 h at 4°C.
After centrifugation, cells were washed 4 times with cold complete growth
medium to remove any residual compound/unbound virus and returned
to 37°C and 5% CO2.
Viral RNA quantification. For the direct quantification of HCVcc/
VSV-Gpp RNA, the total RNA from PD-treated HCVcc/VSV-Gpp and
cells infected with these viruses was isolated using the EZNA viral RNA kit
(Omega Bio-Tek) and total RNA kit (Omega Bio-Tek), respectively. The
amount of HCV RNA was quantified via TaqMan quantitative reverse
transcription-PCR (qRT-PCR) (qScript one-step fast kit; Quanta Biosci-
ences, Gaithersburg, MD) using previously described primers (44). The
amount of lentiviral RNA was quantified using SYBR green qRT-PCR
(one-step SYBR green kit; Quanta Biosciences) with primers pV1-
qPCR-F (5=-ACGGCCTCTAGAATGAGC-3=) and pV1-qPCR-R (5=-AC
AGCTGCTCGAGGTT-3=).
Due to the large amount of residual provirus-encoding DNA present
in the pseudoparticle preparations obtained from transfected 293T cells,
we were not able to directly quantify the viral RNA. Instead, repackaged
pseudoparticles were used in all experiments involving the direct quanti-
fication of viral RNA by qRT-PCR. Briefly, VSV-Gpp constructed from
pV1-B (9, 13, 47) were used to transduce Huh-7.5 cells. Three days later,
these Huh-7.5 cells were transfected with plasmids carrying HIV gag-pol
and vesicular stomatitis virus (VSV)-G envelope protein to produce
freshly repackaged pseudoparticles. Pseudoparticles serially repackaged in
this manner at least 3 times were used in experiments requiring the direct
quantification of viral RNA.
Gluc reporter assay. Supernatant Gluc activities were quantified 48 or
72 h postinfection with the relevant virus using a BioLux Gaussia lucifer-
ase assay kit (NewEngland BioLabs) and normalized to viable cell levels as
determined via the CellTiter-Glo luminescent cell viability assay (Pro-
mega).
Liposome dye release assay. Liposomes composed of 36 mg POPC
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), 39 mg DPPC (1,2-
dipalmitoyl-sn-glycero-3-phosphocholine), 4 mg POPS (1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine), and 21 mg cholesterol per 100
mg, without or with 100 mM sulforhodamine B (SulfoB; Avanti Polar
Lipids, Inc.), were prepared as described previously (7) and sized via re-
peated extrusion through a 100-nm polycarbonate membrane filter
(Avanti Polar Lipids, Inc.). Dye release assays were performed in aGemini
EM spectrofluorometer (Molecular Devices, San Francisco, CA). One l
PD (30mM), 0.24l C5A (10mg/ml), or 1l DMSOwas added to 100l
liposomes (100 M; 0.06 mg/ml) in phosphate-buffered saline (PBS) in
384-well plates, and membrane disruption was gauged from the increase
in SulfoB fluorescence at excitation and emission wavelength settings of
544 and 590 nm, respectively, 5 min posttreatment. The fluorescence in-
tensity corresponding to 100% SulfoB release was obtained by liposome
disruption with 0.1% Triton X-100.
HIV-1, HIV-2, and SIV infectivity assays. TZM-bl cells (5) (100,000
cells/ml) were exposed to HIV or SIV (1 ng of p24/p27) for 4 h together
with increasing concentrations of PD or DMSO control and washed, and
then infection was measured 48 h later by -galactosidase activity. Pri-
mary HIV-1, HIV-2, and SIV were obtained through the National Insti-
tutes of Health (NIH) AIDS Research and Reference Reagent Program
and amplified in activated human peripheral blood mononuclear cells
(PBMC; activated by phytohemagglutinin/interleukin-2 treatment). To
determine the anti-HIV effect of PD in genital fluids, the same TZM cells
were exposed to HIV strain JR-CSF(1 ng of p24) for 4 h together with
increasing concentrations of PD diluted in cervical fluids (pool of four
donors) (2).
HIV-1 sedimentation assay. Purified HIV-1 (20 ng of p24 of NL4.3)
was microcentrifuged for 90 min at 4°C to remove free capsid, resus-
pended in PBS, exposed to PD or DMSO medium control, and loaded
over a 20 to 70% sucrose gradient. After ultracentrifugation at 20,000 rpm
for 24 h in an SW-41 T rotor, fractions (1ml) were collected and tested for
their content of viral proteins. HIV-1 capsid was detected by p24 enzyme-
linked immunosorbent assay (ELISA). Reverse transcriptase (RT) activity
was measured using a polyribonucleotide template (exo-RT assay) (1).
The density of each sucrose gradient fraction was determined by measur-
ing the refractive index.
HIV-1 cell-to-cell transfer assay. Blood-derived immature dendritic
cells (DC) were plated at 50,000 cells per well in 96-well V-bottom plates
(BD Biosciences). Cells were incubated with wild-type NL4.3-eGFP (X4),
NL4.3-BaL-eGFP (R5), or the single-round NL4.3Env-eGFP pseu-
dotyped virus with NL4.3 gp160 (X4) (25 ng of p24) for 2 h at 37°C.
Medium supplemented with either PD or DMSO then was added and
incubated with DC for 2 h. Cells were washed three times with warm
medium, and CCR5 Jurkat T cells (100,000 cells) were added. Cells were
cultured in a flat-bottom 96-well plate, harvested after 3 days, and fixed in
4% paraformaldehyde-PBS, and green fluorescent protein (GFP) expres-
sion was measured by a fluorescence-activated cell sorter (FACS). The
percentage of infected Jurkat T cells was selectively quantified by gating T
cells using an anti-CD3 antibody. Virus isolates used in this study were
pNL4.3-BaL (R5), in which wild-type NL4.3 envelope was switched for
the R5 BaL envelope; pNL4.3Env, which lacks gp160; pNL4.3-eGFP
(X4); and pNL4.3-BaL-eGFP (R5), which encode the GFP gene instead of
the Nef gene (14).
RESULTS
PD 404,182 is virucidal against HCV and pseudotyped lentivi-
ruses. Previously, we showed that PD alleviates a HCVcc-induced
cytopathic effect and inhibits the cellular entry of HIV lentivirus
pseudotyped with envelope glycoproteins from the H77 isolate of
HCV and vesicular stomatitis virus (VSV). In this study, we show
that PD inhibits HCV infection by inactivating extracellular viri-
ons. As shown in Fig. 1A and B, PD dose dependently inactivates
cell-free HCVcc with an IC50 of 11 M. To explore the possibility
that the antiviral activity of PD is independent of the viral enve-
lope protein, we incubated PDwithHIV lentiviruses pseudotyped
with three additional envelope proteins derived frommurine leu-
kemia virus (MLV) (5), Sindbis virus (SINV) (29), and HIV (25).
PD exhibits similar antiviral activity against all of these pseu-
dotyped lentiviruses (see Fig. S1 in the supplemental material),
indicating that the antiviral activity derives from interference with
a viral structural component other than the envelope proteins.
We next set out to evaluate whether PD treatment causes the
lysis of the virus membrane/capsid. Supernatant containing lenti-
virus pseudotyped with vesicular stomatitis virus envelope glyco-
protein (VSV-Gpp) or HCVcc was treated with PD or with the
corresponding concentration of the solvent DMSO at 37°C for 30
min in the presence of RNase A prior to the quantification of viral
RNA and infectivity. As shown in Fig. 1C, treatment with 150M
PD induces the RNase-mediated degradation of VSV-Gpp RNA
by30-fold (3.7% remaining) and inhibits supernatant infectiv-
ity by 1,000-fold (0.1% remaining) relative to that of DMSO-
treated virus. The significant fold difference between virus inacti-
vation and virion lysis, which becomes more pronounced with
shorter virus-PD preincubation times (see Fig. 4B), suggests that
virion lysis is not required for PD-mediated virus inactivation. A
similar effect was observed with the virucidal peptide C5A, which
showed100-foldmore virion inactivation than lysis (7). Little to
no virion lysis was observed in 150 M PD-treated HCVcc, de-
spite the10-fold inhibition of virus infectivity. A low but repro-
ducible level ofHCVcc virion lysis (27%)was observed (see Fig. S2
in the supplemental material) only when a higher concentration
of PD (300 M) was used in combination with a prolonged incu-
bation at 37°C (90 min). Since PD appears to significantly inacti-
vate but only poorly lyse HCVcc, we asked ourselves whether PD-
Chamoun et al.
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treatedHCVcc particles that resist lysis by PD retain their ability to
attach to the surface of cells. The measurement of cell surface-
associated virus via qRT-PCR revealed that PD-treated HCVcc
binds to cells comparably to control DMSO-treated virus, sug-
gesting that treatment with the compound inhibits a postattach-
ment step for virions that remain intact (see Fig. S2). The ability of
PD to physically inactivate both VSV-Gpp and HCVcc, two very
different viruses, combined with the observation that the com-
pound does not seem to significantly distinguish between lentivi-
ruses pseudotyped with different envelope proteins (see Fig. S1),
suggests that its antiviral activity is mediated through a common
non-envelope protein structural component.
To evaluate the antiviral specificity of PD,we tested the effect of
the compound on two other enveloped viruses, SINV, an alpha-
virus (38), andDengue virus (DenV), a flavivirus closely related to
HCV (18). As shown in Fig. S3 in the supplemental material, PD
exhibits no significant inhibitory effect on the infectivity of SINV
and DenV at 300 M. Interestingly, despite the observed absence
of antiviral activity against SINV, PD was found to exhibit strong
antiviral activity against lentivirus pseudotyped with SINV enve-
lope protein (see Fig. S1), underscoring the nonspecific nature of
the antiviral effect on pseudotyped lentiviruses. The neutrality of
PD toward SINV and DenV suggests that PD exerts its antiviral
effect by specifically interfering with a structural feature common
to HCVcc and pseudotyped lentiviruses but not present on SINV
and DenV.
PD inactivates a broad range of primary HIV isolates and
related retroviruses. Since PD strongly inactivates all of the pseu-
dotyped lentiviruses we tested regardless of the envelope protein
(see Fig. S1 in the supplemental material), we asked ourselves
whether PD also inactivates primaryHIV and related retroviruses.
Using CD4 HeLa cells (TZM-bl cells [34]) that produce
-galactosidase in response to HIV infection, we determined the
antiviral activity of PD on 14 isolates of HIV-1 which represent
various subtypes and which use different coreceptors, either
CCR5 (R5 viruses) orCXCR4 (X4 viruses), to infect cells, aswell as
isolates of other retroviruses, including HIV-2 and simian immu-
nodeficiency virus (SIV). Viruses were added to TZM-bl cells to-
gether with PD for 4 h, cells werewashed, and infectionwas scored
48 h later. As shown in Table 1, PD effectively inhibits all of
the tested isolates of HIV and SIV at submicromolar to low-
micromolar concentrations, on par with the potency of the viru-
cidal amphipathic peptide C5A (3, 7). Similar anti-HIV potency
was observed when PD was diluted in cervical fluids (Table 1).
To probe the effect of PD on the structural integrity of HIV
particles, we carried out a virus sedimentation assay. Purified
HIV-1 (X4 NL4.3) (20 ng of p24 in PBS) was incubated in the
presence or absence of PD (10M) for 30min at 37°C and loaded
onto a 20 to 70% sucrose gradient. Each fraction was analyzed for
the amount of HIV capsid and reverse transcriptase (RT) (Fig. 2).
Untreated virus (capsid andRTproteins) sediments at a density of
1.16 g/cm3. In contrast, viral capsid and RT relocate to the top of
the gradient in PD-treated virus preparations, indicating that PD
exerts its virucidal effect on HIV and retroviral particles by com-
promising virion integrity. This observation is consistent with the
lysis of pseudotyped lentivirus shown in Fig. 1C.
PD does not lyse or interact with liposomal membranes. Be-
cause the antiviral potency of PD is virus envelope protein inde-
pendent, we investigated the possibility that PD exerts its anti-
viral activity via the disruption of the viral lipid membrane.
Cholesterol-phospholipid liposomes entrapping the fluorescent
dye sulforhodamine B (SulfoB) were incubated with PD, C5A, or
TABLE 1 PD 404,182 inhibits a broad spectrum of HIV and related viruses
Isolate Clade
Coreceptor
usage
IC of PD (M) ina:
DMEMb Cervical Fluidc
IC50 IC90 IC50 IC90
Primary HIV-1
92RW021 A R5 0.43 0.03 3.8 0.3 0.67 0.04 4.4 0.2
92UG029 A X4 1.18 0.02 4.4 0.2 1.47 0.1 5.3 0.3
92TH026 B R5 0.35 0.01 2.8 0.2 0.61 0.03 3.3 0.1
92HT599 B X4 1.8 0.1 5.9 0.3 2.2 0.04 6.4 0.5
93IN101 C R5 1.5 0.2 5.1 0.3 1.8 0.1 5.5 0.2
98IN017 C X4 0.4 0.1 1.9 0.2 0.7 0.05 2.4 0.2
92UG005 D R5 1.26 0.2 5.3 0.4 1.39 0.11 5.7 0.3
92UG024 D X4 0.33 0.02 1.4 0.2 0.55 0.04 1.8 0.2
92TH006 E R5 1.8 0.2 6.6 0.4 2.3 0.1 7.6 0.6
93TH053 E X4 1.4 0.2 5.3 0.3 1.8 0.2 6.4 0.4
93BR029 F R5 0.7 0.1 3.5 0.2 1.2 0.1 4.6 0.3
93BR020 F X4 1.4 0.2 6.9 0.4 1.9 0.2 7.5 0.4
RU132 G R5 0.6 0.2 3.1 02 0.9 0.2 3.9 0.5
Jv1083 G R5 1.1 0.2 3.9 0.3 1.5 0.2 4.7 0.1
Other retroviruses
SIVmac251 32H 1.1 0.2 6.2 0.4
SIVsyk1.2 1.9 0.3 5.4 0.2
HIV-2CDC310342 1.8 0.2 4.7 0.2
HIV-27312A 2.2 0.3 6.8 0.3
a Errors represent the SD from 2 independent experiments carried out in duplicate.
b IC50 is measured with PD diluted in DMEM with 10% fetal bovine serum.
c IC50 is measured with PD diluted in cervical fluids (pool of 4 donors).
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DMSO. The disruption of the liposomes is accompanied by the
dequenching of the fluorescent dye, and it was quantified bymea-
suring the resultant fluorescence release. PD does not interfere
with SulfoB fluorescence (data not shown). C5A, a peptide de-
rived from HCV NS5A protein that has been shown to lyse lipo-
somes, was used as a positive control (7). As shown in Fig. 3A, PD
is unable to permeabilize liposomes after incubation for 5min.No
significant increase in fluorescence intensity was observed even
after prolonged (up to 3 h) incubationwith PD (see Fig. S4A in the
supplemental material).
We next set out to determine whether PD associates with lipo-
somal membranes without causing lysis. Since PD is not inher-
ently fluorescent, we were unable to directly measure the interac-
tion of PD with liposomes. Instead, we sought to determine
whether the inhibitory effect of PD during infection can be re-
versed by the addition of liposomes. VSV-Gpp (3.4 104 TCID50/
ml) mixed with PD and increasing concentrations of liposomes
was used to infect Huh-7.5 cells. The presence of liposomes was
not able to reverse PD’s antiviral effect (Fig. 3B), suggesting that
PD does not significantly interact with liposomes. In fact, lipo-
FIG 2 PD destabilizes HIV-1 particles. NL4.3 virus (20 ng of p24) was incubated in the presence or absence of 10 MPD for 30 min at 37°C and loaded over a
sucrose density gradient. The quantification of HIV-1 capsid and RT proteins was conducted by p24 ELISA and exoRT assay, respectively. All data are the
means SD from two independent experiments carried out in duplicate.
Chamoun et al.
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somes of different lipid compositions were tested, but none were
found to reverse the antiviral effect of PD (see Fig. S4B andC in the
supplemental material).
The virucidal activity of PD is temperature, time, and virus
dilution dependent. To further elucidate the antiviral effect of
PD, VSV-Gpp was incubated with PD (300 M) or DMSO (1%)
at various temperatures and for various times, and the amount of
remaining viral RNA and the infectivity of the virus/compound
mixtures were determined thereafter. The virion lysis activity of
PD was found to be temperature dependent, as PD disrupts the
virus following a 30-min incubation at 37°C but is less disruptive
at 25°C and exhibits no measurable virion lysis at 4°C (Fig. 4A),
indicating that a minimum level of membrane fluidity is required
for PD to lyse the virus membrane/capsid. A similar trend was
observed for viral infectivity. PD rapidly inactivates pseudotyped
lentivirus at 37°C as determined by the loss of viral RNA and
infectivity (Fig. 4B). More than 99.5% of the VSV-Gpp was inac-
tivated within 5 min when in contact with 300 MPD. However,
only 40% of the virions were compromised to the point of
genomicRNA release for the same 5-min virus-PDpreincubation,
indicating that virion lysis is not required for virus inactivation.
The sensitivity of virus to PD also is virus dilution dependent
(see Fig. S5 in the supplemental material). The IC50s of PD for cell
culture-produced VSV-Gpp virus stocks diluted 5- and 500-fold
in fresh complete growthmedium (DMEMplus 10% FBS) are 4.6
and 0.5 M, respectively. Similarly, the IC50s for HIVpp (lentivi-
rus pseudotyped with envelope protein from Bal.01 HIV) are 24.6
and 0.3 M for undiluted and 100-fold-diluted virus. Further
studies demonstrated that PD is inactivated by amolecule(s) pres-
ent in conditioned cell culture medium, as virus diluted in condi-
tioned medium is significantly less sensitive to inactivation by PD
than the same virus diluted in fresh complete medium (Fig. 4C).
To gauge the approximate size of the molecule(s) responsible for
neutralizing the antiviral effect of PD, we fractionated condi-
tionedmedium fromHuh-7.5 cells by passage through ultrafiltra-
tion membranes with different pore sizes and found that the fil-
trate from a 3-kDa membrane is able to inactivate PD to the same
extent as the unfiltered conditionedmedium (Fig. 4D). This result
suggests that the molecule(s) responsible for neutralizing PD is
relatively small (3 kDa). Analysis using liquid chromatography-
mass spectrometry (LC-MS) demonstrated that PD is degraded
(data not shown), possibly by reacting with a small molecule se-
creted by cells, rendering it less active against pseudotyped lenti-
virus. Although the presence of 10% fetal bovine serum appears to
have no inhibitory effect on PD’s antiviral activity (Fig. 4C), 10%
human serumyielded a significant (50- to 80-fold) increase in IC50
(see Fig. S6 in the supplemental material), suggesting the presence
of PD-inhibitory factors in human serum in addition to cell cul-
ture medium conditioned by human cancer cells. It is worth not-
ing that similar IC50 and IC90 values were obtained with PD di-
luted in DMEM or cervical fluids (Table 1), indicating that
cervical fluids are free of molecule(s) that detectably inhibit the
antiviral activity of PD.
Antiviral effect of PD before, during, and after HIV-1 expo-
sure and on cell-to-cell transmission of HIV-1. PD exhibits
strong virucidal activity against pseudotyped lentivirus and pri-
maryHIV, raising the possibility of its use as a topical microbicide
for preventing the sexual transmission of HIV-1. To shed light on
this possibility, we investigated the antiviral effect of PD when the
compound was added to cells at various time points relative to the
addition of HIV-1. PD was added to TZM-bl cells at 1, 2, 4, or 16
h before the addition ofHIV-1 (R5 JR-CSF) (1 ng of p24), together
with the virus (time zero), and at 1, 2, 4, or 8 h after the addition of
the virus, and infectivity was quantified 48 h after virus addition.
As shown in Fig. 5A, PD significantly inhibits HIV-1 infection
when added together with the virus (time zero) and retains its
full potency up to 8 h before the addition of the virus. However,
PD loses its antiviral effect when added to cells after virus in-
oculation (Fig. 5A, 1, 2, 4, and 8 h after treatment). This result
suggests that PD is not able to disrupt intracellular virus. In
addition, extended (16 h) preincubation of PD with cells
prior to virus inoculation also significantly reduces the com-
pound’s antiviral efficacy.
Since HIV-1 can be transmitted either as a cell-free or cell-
associated virus, we examined the effect of PD on cell-to-cell
transmission. Specifically, we examined the capacity of PD to pre-
vent the dendritic cell (DC)-mediated transmission of HIV-1.We
took advantage of a replication-defective virus (NL4.3Env-
eGFP) which does not encode Env but which has been pseu-
dotyped with HIV-1 Env. (These pseudotyped viruses infect cells
because they contain Env.) However, cells that have been infected
by pseudotyped viruses cannot produce infectious viruses, be-
cause de novo viruses do not encode Env. Thus, the use of pseu-
dotyped viruses allowed the analysis of the effect of PD on the
transmission of infectious particles from DC to T cells indepen-
dently of DC infection. DCwere incubated with wild-type NL4.3-
eGFP (X4 virus) and NL4.3-BaL-eGFP (R5 virus) or pseudotyped
NL4.3Env-eGFP/gp160 Env viruses (25 ng of p24). Two hours
later, at which time the attachment of the virus onto DC is com-
pleted (15), PD (10M)was added. After 2 h, DCwere washed to
remove both free virus and PD. To measure DC-T cell transmis-
sion, Jurkat T cells were added for 3 days, and the percentage of
infected T cells (gated with an anti-CD3 antibody) was analyzed
by FACS. Only pseudotyped viruses that have been rapidly trans-
FIG 3 PD does not lyse or directly interact with liposomal membranes. (A)
The ability of PD (300 M), the virucidal peptide C5A (10 M), and solvent
DMSO (1%) to permeabilize liposomes entrapping SulfoB was determined by
a liposome dye release assay. A relative fluorescence intensity of 100 cor-
responds to SulfoB release resulting from liposome disruption with 0.1%
Triton X-100. (B) VSV-Gpp (harboring pV1-Gluc;1.7 107 TCID50/ml)
was diluted 500-fold in fresh complete growth medium and preincubated
with PD for 30 min at 37°C in the presence or absence of various concen-
trations of liposomes. The virus-PD-liposome mixtures then were used to
spinoculate Huh-7.5 cells, and infectivity was quantified by measuring the
supernatant activity of the Gluc reporter 48 h posttransduction. All data are
the means  SD from two independent experiments carried out in tripli-
cate.
Virucidal Molecule against HCV and HIV
February 2012 Volume 56 Number 2 aac.asm.org 677
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
ferred from DC to T cells through the virological synapse (inde-
pendently of DC infection) can infect T cells. Indeed, progeny
viruses from DC infected by pseudotyped viruses can no longer
infect T cells because they do not encode Env. Because DC were
washed before adding T cells, the T-cell infection by the pseu-
dotyped virus observed in Fig. 5B could arise only from pseu-
dotyped particles that were transferred fromDC to T cells. Impor-
tantly, PD added to DC prevents subsequent T-cell infection with
the pseudotyped virus. This finding suggests that PD also can in-
activate DC-bound virus, preventing HIV transmission from DC
toT cells. These results suggest that, unlike neutralizing antibodies
(14), PD blocks the cell-to-cell transfer of HIV even when trans-
mission occurs via the virological synapse.
DISCUSSION
In this study, we report a small molecule, PD 404,182 (PD), that
renders extracellular cell culture-produced HCV, pseudotyped
lentiviruses, and several primary isolates of HIV and SIV nonin-
fectious. In the case of pseudotyped lentivirus and primary HIV,
the antiviral activity of PD appears to be due to the physical dis-
ruption of the virion. The antiviral action of PD is very rapid, as
99.5% of the lentivirus becomes inactivated within 5 min of
FIG 4 PD exhibits virucidal activity that is temperature- and virus dilution-dependent and virus lysis activity that is time dependent. Undiluted VSV-Gpp
(harboring pV1-B or pV1-Gluc;5105 TCID50/ml) was treated with 300 M PD, 0.1% Triton X-100, or 1% DMSO in the presence of 7 ng/ml RNase A for
60 min at different temperatures (A) or at 37°C for different times (B). Viral RNA was isolated thereafter and quantified using qRT-PCR. Viral infectivity was
determined by measuring the supernatant Gluc reporter activity of Huh-7.5 cells 48 h postinoculation with 1,000-fold-diluted virus-PD mixtures. For virus
dilution studies, VSV-Gpp stock (harboring pV1-Gluc; 1.7  107 TCID50/ml) was diluted 500-fold in medium comprising different proportions of condi-
tioned and fresh complete media (all containing 10% FBS) or fresh serum-free medium (C), or the flowthrough of conditioned medium size-fractionated
through membranes with pores of the indicated size prior to pretreatment with PD at 37°C for 30 min (D). PD-treated viral samples were used to spinoculate
naïve Huh-7.5 cells. Infectivity was quantified 2 days later by measuring the supernatant activity of the Gluc reporter. All data are the means  SD from two
independent experiments carried out in duplicate.
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contact with 300 M PD at 37°C. However, only 40% of the
lentiviruses were lysed in the same period, indicating that PD in-
activates pseudotyped lentiviruses andHIVby physical disruption
that does not necessitate the complete lysis of virions. PD expo-
sure does not appear to significantly rupture HCV or inhibit its
attachment to cells, even with 90min of exposure at 37°C (see Fig.
S2 in the supplemental material), despite the inactivation of ex-
tracellular virus, suggesting a subtle disruption of virions (e.g., by
irreversibly interfering with membrane fluidity or curvature) that
causes the inhibition of a postattachment step, such as endocytosis
or fusion with the endosomal membrane. Encouragingly, PD ex-
hibits very low cytotoxicity in several human cell lines (CC50,
300M; see Fig. S7 in the supplemental material). The selectiv-
ity index (CC50/IC50) of PD is 300 for HIV and 27 for HCV.
PD was originally synthesized by Birck et al. as an inhibitor of
bacterial KDO 8-P synthase (1a) and was recently found to also
affect angiogenesis (21) and mammalian circadian rhythms (19).
Intriguingly, despite exhibiting strong lysis of virions derived
from the HIV capsid, PD does not directly lyse liposomes and
shows no attenuation in antiviral activity when preincubated with
liposomes, which is suggestive of little to no direct interaction with
lipid membranes. The antiviral action of PD thus appears to be dif-
ferent from that reported for the amphipathic virucidal peptide C5A
(3, 7), which lyses both virions and liposomal membranes, and the
membrane-intercalating virucidal molecule LJ001 (46), whose anti-
viral effect is attenuated by preincubation with liposomes. It is con-
ceivable that PD disrupts the structural integrity of virions by selec-
tively interacting with a feature of virions that involves an interplay
between twoormore structural components (e.g., lipid membrane
and envelope protein/capsid). We also cannot rule out the pos-
sibility that PD interferes with other virion structural compo-
nents not represented in the liposomemodel, for example, sites
that are glycosylated or phosphorylated (4, 30, 35).
The virion lysis activity of PD is temperature dependent, sug-
gesting that a minimal level of viral membrane fluidity is required
to sufficiently compromise virion integrity to the point of viral
RNA release. PD is inactivated by human serum and medium
conditioned by human cell culture, possibly by interacting with
one ormore smallmolecules/peptides secreted by humans but not
bovine cells.
FIG 5 Effect of PD onHIV-1 infection. (A) Antiviral effect of PD before, during, and after virus exposure. PD (10M) or just growthmedium (DMSO control)
was added to TZM-bl cells 1, 2, 4, 8, or 16 h before (negative values on the y axis) or after (positive values on the y axis) the addition of HIV-1 (R5 JR-CSF) (1 ng
of p24) or together (time zero) with the virus. Infection was quantified 48 h later via the measurement of -galactosidase activity. (B) DC (105 cells) were
incubated for 2 h at 37°Cwithwild-typeNL4.3-eGFP (X4) andNL4.3-BaL-eGFP (R5) viruses orwith the pseudotypedNL4.3Env-eGFP/gp160X4 Env virus (25
ng of p24). PD (10M) or control DMSOmediumwas added 2 h later. DCwere washed 2 h after adding PD, Jurkat T cells (100,000 cells) were added for 3 days,
and the percentage of infected Jurkat T cells (GFP) was analyzed by flow cytometry. Error bars represent standard errors of duplicates from two independent
experiments.
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A striking feature of PD is its highly specific inactivation of
certain viruses (only HCV, HIV, and related retroviruses were
found to be inactivated in this study) without strong association
directly with or disruption of lipid membranes in general, as evi-
dent from our liposome studies. PD exhibited no significant anti-
viral effect onDengue virus, an enveloped flavivirus closely related
to HCV, or cell culture-produced Sindbis virus, an enveloped al-
phavirus (see Fig. S3 in the supplemental material). Like HCV,
Dengue virus acquires the viral envelope by budding into the en-
doplasmic reticulum lumen and is able to undergo intensive struc-
tural rearrangement in an infected cell (45). On the other hand,
Sindbis virus, like HIV, buds from the plasma membrane and
contains an envelope rich in cholesterol and sphingolipid mole-
cules (20). We have yet to determine the antiviral effect of PD on
other enveloped or nonenveloped viruses. The narrow target spec-
trum of PD as determined by our studies on a limited range of
viruses, combined with the absence of nonspecific lysis of or asso-
ciation with lipidmembranesmay, at least in part, account for the
molecule’s very low cytotoxicity.
Our studies bring to light some limitations of PD as an antiviral
agent. Although PD effectively inactivates extracellular virus, it
appears to be ineffective against intracellular virus, possibly due to
a poor ability to enter cells and/or intracellular conversion to an
inactive metabolite. Furthermore, human serum and the ex-
tended (16 h) preincubation of PD with cells prior to virus in-
oculation appears to significantly reduce its antiviral efficacy. Our
observation that the antiviral effect of PD is suppressed by a mol-
ecule(s) secreted by cells into the surrounding growth medium
may be responsible for the latter phenomenon. Since we found
that PD retains its full antiviral activity in cervical fluids, the PD-
neutralizing molecule(s) present in human serum and condi-
tioned cell culture growth medium is likely physiologically irrele-
vant in the case of the development of PD as a topical microbicide
for the treatment/prevention of HIV infection.
It is estimated that there are approximately 4 million new in-
cidences of HIV infection each year, mostly transmitted through
heterosexual intercourse (6). The development of a vaginal (or
rectal) microbicide against HIV would represent a major stride
toward slowing the global spread of HIV (22). Despite the poor
antiviral efficacy of PD against intracellular virus and in medium
conditioned by human cell growth, this compound possesses sev-
eral desirable attributes that make it an attractive candidate anti-
HIV microbicide. Most notably, PD (i) exhibits antiviral activity
against a broad range of primary HIV-1 isolates, HIV-2, and SIV;
(ii) retains full anti-HIVpotency for 8 hwhen in contactwith cells;
(iii) is effective against both cell-free and cell-associated HIV and
inhibits HIV transmission from DC to T cells; (iv) retains full
anti-HIVpotency in cervical fluids; and (v) irreversibly inactivates
HIV predominantly through virion disruption with an activity
that appears to be independent of specific virus envelope proteins.
Drugs that target viral proteins mediating the replication of viral
nucleic acids or virus attachment to target cells often foster the
emergence of escape mutants (33). The antiviral action of PD on
critical components of the virus other than specific virus envelope
proteins makes the development of drug-resistant mutant viruses
less likely.
Several candidate anti-HIVmicrobicides exist (11, 24, 39), but
only a handful exhibit an ability to strongly and irreversibly dis-
rupt virions without being detrimental to cells (7, 17). PD 404,182
is an anti-HIV compound with a unique mode of action and rep-
resents a useful molecular scaffold for the generation of new anti-
HIV-1 microbicides. Finally, the observation that PD 404,182 is
able to inactivate both HCV and HIV and the unique antiviral
action of this small molecule justify further studies of PD 404,182
and derivatives thereof to determine antiviral effects upon other
enveloped and nonenveloped viruses.
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